NeuroPace (NPCE) Financials

$18.20 +0.21 (+1.14%)

As of 01:33 PM Eastern

Annual Income Statements for NeuroPace

This table shows NeuroPace's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-27	-33	-47
Consolidated Net Income / (Loss)	-27	-33	-47
Net Income / (Loss) Continuing Operations	-27	-33	-47
Total Pre-Tax Income	-27	-33	-47
Total Operating Income	-22	-27	-41
Total Gross Profit	59	48	32
Total Revenue	80	65	46
Operating Revenue	80	65	46
Total Cost of Revenue	21	17	13
Operating Cost of Revenue	21	17	13
Total Operating Expenses	81	75	73
Selling, General & Admin Expense	57	55	51
Research & Development Expense	24	21	22
Total Other Income / (Expense), net	-5.47	-5.78	-6.29
Interest Expense	8.80	8.52	7.53
Interest & Investment Income	3.02	3.05	1.58
Other Income / (Expense), net	0.30	-0.32	-0.34
Basic Earnings per Share	($0.93)	($1.27)	($1.91)
Weighted Average Basic Shares Outstanding	29.13M	25.85M	24.59M
Diluted Earnings per Share	($0.93)	($1.27)	($1.91)
Weighted Average Diluted Shares Outstanding	29.13M	25.85M	24.59M
Weighted Average Basic & Diluted Shares Outstanding	32.56M	28.34M	25.10M
Cash Dividends to Common per Share	$0.00	$0.00	-

This table shows NeuroPace's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Consolidated Net Income / (Loss)	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Net Income / (Loss) Continuing Operations	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Total Pre-Tax Income	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Total Operating Income	-3.65	-4.24	-6.23	-7.55	-5.05	-5.95	-7.85	-8.32	-9.86	-10
Total Gross Profit	16	15	14	13	14	12	12	10	8.80	7.97
Total Revenue	21	21	19	18	18	16	17	14	13	11
Operating Revenue	21	21	19	18	18	16	17	14	13	11
Total Cost of Revenue	5.28	5.64	5.12	4.78	4.47	4.19	4.54	4.10	3.99	3.19
Operating Cost of Revenue	5.28	5.64	5.12	4.78	4.47	4.19	4.54	4.10	3.99	3.19
Total Operating Expenses	20	20	20	21	19	18	20	19	19	18
Selling, General & Admin Expense	14	14	14	15	13	13	14	13	14	13
Research & Development Expense	6.05	5.75	6.07	5.78	5.38	4.80	5.34	5.26	5.09	5.61
Total Other Income / (Expense), net	-1.60	-1.21	-1.28	-1.38	-1.15	-1.31	-1.27	-2.06	-1.29	-1.59
Interest Expense	2.19	2.18	2.17	2.26	2.24	2.19	2.13	1.97	1.94	1.91
Interest & Investment Income	0.68	0.75	0.76	0.83	0.82	0.77	0.73	0.73	0.80	0.42
Other Income / (Expense), net	-0.09	0.22	0.12	0.05	0.27	0.12	0.12	-0.82	-0.15	-0.10
Basic Earnings per Share	($0.16)	($0.19)	($0.26)	($0.32)	($0.22)	($0.28)	($0.36)	($0.41)	($0.44)	($0.48)
Weighted Average Basic Shares Outstanding	29.13M	29.44M	28.85M	28.29M	25.85M	26.02M	25.47M	25.10M	24.59M	24.73M
Diluted Earnings per Share	($0.16)	($0.19)	($0.26)	($0.32)	($0.22)	($0.28)	($0.36)	($0.41)	($0.44)	($0.48)
Weighted Average Diluted Shares Outstanding	29.13M	29.44M	28.85M	28.29M	25.85M	26.02M	25.47M	25.10M	24.59M	24.73M
Weighted Average Basic & Diluted Shares Outstanding	32.56M	29.85M	29.20M	28.77M	28.34M	26.28M	25.86M	25.41M	25.10M	24.90M

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-4.63	11	-13
Net Cash From Operating Activities	-18	-20	-37
Net Cash From Continuing Operating Activities	-18	-20	-37
Net Income / (Loss) Continuing Operations	-27	-33	-47
Consolidated Net Income / (Loss)	-27	-33	-47
Depreciation Expense	0.21	0.17	0.27
Amortization Expense	1.79	1.72	2.98
Non-Cash Adjustments To Reconcile Net Income	13	12	12
Changes in Operating Assets and Liabilities, net	-5.45	-1.07	-4.79
Net Cash From Investing Activities	8.99	23	24
Net Cash From Continuing Investing Activities	8.99	23	24
Purchase of Property, Plant & Equipment	-0.31	-0.17	-0.60
Sale and/or Maturity of Investments	9.30	23	24
Net Cash From Financing Activities	4.33	8.13	0.49
Net Cash From Continuing Financing Activities	4.33	8.13	0.49
Repurchase of Common Equity	0.00	-0.31	-0.35
Issuance of Common Equity	5.21	8.69	0.90
Other Financing Activities, net	-0.88	-0.26	-0.06
Cash Interest Paid	6.23	4.48	4.46

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-1.99	2.57	-0.15	-5.06	8.34	1.86	1.14	0.12	0.92	-0.01
Net Cash From Operating Activities	-4.80	-1.72	-3.90	-7.53	-3.34	-2.30	-4.36	-9.70	-7.84	-6.98
Net Cash From Continuing Operating Activities	-4.80	-1.72	-3.90	-7.53	-3.34	-2.30	-4.36	-9.70	-7.84	-6.98
Net Income / (Loss) Continuing Operations	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Consolidated Net Income / (Loss)	-5.25	-5.45	-7.51	-8.93	-6.20	-7.26	-9.12	-10	-11	-12
Depreciation Expense	0.05	0.06	0.06	0.05	0.04	0.04	0.05	0.05	0.05	0.06
Amortization Expense	0.45	0.44	0.44	0.46	0.45	0.44	0.42	0.41	0.76	0.74
Non-Cash Adjustments To Reconcile Net Income	2.96	2.68	3.47	3.54	1.75	4.00	2.82	3.86	3.15	3.19
Changes in Operating Assets and Liabilities, net	-3.00	0.55	-0.35	-2.65	0.62	0.48	1.47	-3.64	-0.67	0.82
Net Cash From Investing Activities	1.96	1.40	3.24	2.40	3.47	4.19	5.30	10	8.90	6.97
Net Cash From Continuing Investing Activities	1.96	1.40	3.24	2.40	3.47	4.19	5.30	10	8.90	6.97
Purchase of Property, Plant & Equipment	-0.04	-0.10	-0.06	-0.10	-0.03	-0.01	-	-0.13	-0.10	-0.03
Sale and/or Maturity of Investments	2.00	1.50	3.30	2.50	3.50	4.20	5.30	10	9.00	7.00
Net Cash From Financing Activities	0.85	2.90	0.51	0.07	8.21	-0.03	0.20	-0.26	-0.14	-0.01
Net Cash From Continuing Financing Activities	0.85	2.90	0.51	0.07	8.21	-0.03	0.20	-0.26	-0.14	-0.01
Issuance of Common Equity	3.87	0.03	0.58	0.72	8.44	0.01	0.25	0.00	0.21	-
Other Financing Activities, net	-3.02	2.86	-0.07	-0.65	-0.04	-0.04	-0.04	-0.15	-0.00	-0.01
Cash Interest Paid	1.93	1.93	1.19	1.17	1.17	1.16	1.13	1.02	0.98	0.97

This table presents NeuroPace's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	95	108	114
Total Current Assets	81	93	98
Cash & Equivalents	13	18	6.61
Short-Term Investments	39	48	71
Accounts Receivable	13	12	7.48
Inventories, net	13	11	9.71
Prepaid Expenses	2.35	2.74	3.11
Plant, Property, & Equipment, net	1.05	1.00	1.06
Total Noncurrent Assets	12	14	15
Other Noncurrent Operating Assets	12	14	15
Total Liabilities & Shareholders' Equity	95	108	114
Total Liabilities	87	87	79
Total Current Liabilities	15	16	11
Accounts Payable	2.95	2.33	2.15
Accrued Expenses	9.79	11	7.41
Current Deferred Revenue	0.56	1.09	0.00
Other Current Liabilities	1.86	1.63	1.42
Total Noncurrent Liabilities	71	71	68
Long-Term Debt	60	57	53
Other Noncurrent Operating Liabilities	12	14	15
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.01	21	35
Total Preferred & Common Equity	8.01	21	35
Preferred Stock	0.00	0.00	0.00
Total Common Equity	8.01	21	35
Common Stock	539	524	507
Retained Earnings	-531	-504	-471

This table presents NeuroPace's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	96	94	99	99	102	106	120
Total Current Assets	83	80	84	84	87	90	104
Cash & Equivalents	15	13	13	9.72	7.86	6.72	5.69
Short-Term Investments	41	43	46	52	56	61	80
Accounts Receivable	12	11	12	11	11	9.19	7.88
Inventories, net	12	11	11	9.76	10	11	8.58
Prepaid Expenses	2.12	2.08	2.26	1.59	2.05	2.60	2.50
Plant, Property, & Equipment, net	1.04	1.00	1.05	0.95	0.98	1.02	0.89
Total Noncurrent Assets	13	13	14	14	15	15	15
Other Noncurrent Operating Assets	13	13	14	14	15	15	15
Total Liabilities & Shareholders' Equity	96	94	99	99	102	106	120
Total Liabilities	86	85	85	83	81	79	77
Total Current Liabilities	15	13	13	13	12	9.88	9.42
Accounts Payable	2.16	2.29	3.27	1.21	1.81	1.83	1.18
Accrued Expenses	10	7.75	7.29	10	8.18	6.58	7.55
Current Deferred Revenue	0.75	0.81	0.87	-	-	-	-
Other Current Liabilities	1.80	1.74	1.68	1.57	1.52	1.47	0.69
Total Noncurrent Liabilities	72	72	71	70	69	69	68
Long-Term Debt	59	59	58	56	55	54	52
Other Noncurrent Operating Liabilities	12	13	13	14	15	15	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9.82	9.89	14	16	21	27	43
Total Preferred & Common Equity	9.82	9.89	14	16	21	27	43
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	9.82	9.89	14	16	21	27	43
Common Stock	536	530	527	514	512	509	504
Retained Earnings	-526	-520	-513	-498	-490	-481	-460

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	22.14%	43.72%	0.75%
EBITDA Growth	24.34%	32.43%	-32.68%
EBIT Growth	22.27%	33.17%	-41.26%
NOPAT Growth	20.25%	33.39%	-71.86%
Net Income Growth	17.64%	30.00%	-30.49%
EPS Growth	26.77%	33.51%	11.98%
Operating Cash Flow Growth	8.89%	46.56%	-50.01%
Free Cash Flow Firm Growth	5.51%	35.97%	-94.11%
Invested Capital Growth	32.54%	8.49%	32.38%
Revenue Q/Q Growth	4.52%	8.68%	4.10%
EBITDA Q/Q Growth	5.20%	16.03%	-0.84%
EBIT Q/Q Growth	4.67%	15.96%	-2.46%
NOPAT Q/Q Growth	6.06%	15.03%	-2.11%
Net Income Q/Q Growth	3.38%	13.05%	-0.97%
EPS Q/Q Growth	6.06%	14.77%	-106.39%
Operating Cash Flow Q/Q Growth	-8.83%	18.60%	0.97%
Free Cash Flow Firm Q/Q Growth	-7.40%	14.76%	-3.72%
Invested Capital Q/Q Growth	20.59%	2.29%	3.32%
Profitability Metrics	-	-	-
Gross Margin	73.94%	73.56%	71.38%
EBITDA Margin	-24.24%	-39.13%	-83.23%
Operating Margin	-27.12%	-41.54%	-89.62%
EBIT Margin	-26.74%	-42.02%	-90.36%
Profit (Net Income) Margin	-33.97%	-50.38%	-103.43%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	127.02%	119.89%	114.47%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-116.97%	-177.48%	-316.46%
ROIC Less NNEP Spread (ROIC-NNEP)	760.04%	-95.51%	-275.40%
Return on Net Nonoperating Assets (RNNOA)	-72.38%	58.58%	229.50%
Return on Equity (ROE)	-189.35%	-118.91%	-86.96%
Cash Return on Invested Capital (CROIC)	-144.96%	-185.63%	-344.33%
Operating Return on Assets (OROA)	-21.12%	-24.79%	-33.21%
Return on Assets (ROA)	-26.83%	-29.72%	-38.02%
Return on Common Equity (ROCE)	-189.35%	-118.91%	-86.96%
Return on Equity Simple (ROE_SIMPLE)	-338.71%	-159.56%	-135.38%
Net Operating Profit after Tax (NOPAT)	-15	-19	-29
NOPAT Margin	-18.98%	-29.08%	-62.73%
Net Nonoperating Expense Percent (NNEP)	-877.02%	-81.98%	-41.06%
Return On Investment Capital (ROIC_SIMPLE)	-22.46%	-24.51%	-
Cost of Revenue to Revenue	26.06%	26.44%	28.62%
SG&A Expenses to Revenue	71.46%	83.33%	112.79%
R&D to Revenue	29.60%	31.76%	48.21%
Operating Expenses to Revenue	101.06%	115.09%	161.00%
Earnings before Interest and Taxes (EBIT)	-21	-27	-41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-19	-26	-38
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	41.68	13.12	1.07
Price to Tangible Book Value (P/TBV)	41.68	13.12	1.07
Price to Revenue (P/Rev)	4.18	4.14	0.82
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.05	23.44	1.23
Enterprise Value to Revenue (EV/Rev)	4.26	4.00	0.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	7.43	2.76	1.52
Long-Term Debt to Equity	7.43	2.76	1.52
Financial Leverage	-0.10	-0.61	-0.83
Leverage Ratio	7.06	4.00	2.29
Compound Leverage Factor	8.96	4.80	2.62
Debt to Total Capital	88.14%	73.39%	60.34%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	88.14%	73.39%	60.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	11.86%	26.61%	39.66%
Debt to EBITDA	-3.07	-2.22	-1.40
Net Debt to EBITDA	-0.35	0.37	0.65
Long-Term Debt to EBITDA	-3.07	-2.22	-1.40
Debt to NOPAT	-3.92	-2.99	-1.85
Net Debt to NOPAT	-0.45	0.50	0.86
Long-Term Debt to NOPAT	-3.92	-2.99	-1.85
Altman Z-Score	-4.60	-4.07	-5.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.37	5.71	8.90
Quick Ratio	4.33	4.85	7.73
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-19	-20	-31
Operating Cash Flow to CapEx	-5,865.69%	-11,387.86%	-6,114.26%
Free Cash Flow to Firm to Interest Expense	-2.14	-2.34	-4.13
Operating Cash Flow to Interest Expense	-2.04	-2.31	-4.90
Operating Cash Flow Less CapEx to Interest Expense	-2.07	-2.33	-4.98
Efficiency Ratios	-	-	-
Asset Turnover	0.79	0.59	0.37
Accounts Receivable Turnover	6.35	6.61	6.25
Inventory Turnover	1.69	1.65	1.49
Fixed Asset Turnover	77.77	63.30	54.61
Accounts Payable Turnover	7.88	7.72	7.39
Days Sales Outstanding (DSO)	57.48	55.22	58.43
Days Inventory Outstanding (DIO)	215.58	220.76	245.64
Days Payable Outstanding (DPO)	46.33	47.25	49.38
Cash Conversion Cycle (CCC)	226.72	228.74	254.68
Capital & Investment Metrics	-	-	-
Invested Capital	15	11	10
Invested Capital Turnover	6.16	6.10	5.04
Increase / (Decrease) in Invested Capital	3.63	0.87	2.52
Enterprise Value (EV)	341	261	13
Market Capitalization	334	271	37
Book Value per Share	$0.27	$0.79	$1.40
Tangible Book Value per Share	$0.27	$0.79	$1.40
Total Capital	68	78	88
Total Debt	60	57	53
Total Long-Term Debt	60	57	53
Net Debt	6.77	-9.50	-24
Capital Expenditures (CapEx)	0.31	0.17	0.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	10	9.33
Debt-free Net Working Capital (DFNWC)	66	76	87
Net Working Capital (NWC)	66	76	87
Net Nonoperating Expense (NNE)	12	14	19
Net Nonoperating Obligations (NNO)	6.77	-9.50	-24
Total Depreciation and Amortization (D&A)	2.00	1.89	3.25
Debt-free, Cash-free Net Working Capital to Revenue	16.80%	15.34%	20.49%
Debt-free Net Working Capital to Revenue	82.83%	116.92%	190.55%
Net Working Capital to Revenue	82.83%	116.92%	190.55%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.93)	($1.27)	($1.91)
Adjusted Weighted Average Basic Shares Outstanding	29.13M	25.85M	24.59M
Adjusted Diluted Earnings per Share	($0.93)	($1.27)	($1.91)
Adjusted Weighted Average Diluted Shares Outstanding	29.13M	25.85M	24.59M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.56M	28.34M	25.10M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-19	-29
Normalized NOPAT Margin	-18.98%	-29.08%	-62.73%
Pre Tax Income Margin	-33.97%	-50.38%	-103.43%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-2.43	-3.23	-5.46
NOPAT to Interest Expense	-1.72	-2.23	-3.79
EBIT Less CapEx to Interest Expense	-2.46	-3.25	-5.54
NOPAT Less CapEx to Interest Expense	-1.76	-2.25	-3.87
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.93%	-0.74%

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.18%	28.20%	16.63%	25.23%	40.84%	47.23%	61.86%	27.24%	16.30%	7.91%
EBITDA Growth	24.69%	34.25%	22.70%	19.41%	53.18%	43.54%	29.20%	3.01%	-3.56%	-51.74%
EBIT Growth	21.88%	31.04%	20.98%	17.97%	52.16%	43.36%	30.08%	6.44%	-10.96%	-61.15%
NOPAT Growth	27.68%	28.69%	20.68%	9.30%	48.77%	41.66%	28.43%	14.78%	-9.36%	-63.37%
Net Income Growth	15.32%	24.87%	17.65%	13.98%	44.37%	38.42%	28.10%	9.48%	-4.24%	-45.80%
EPS Growth	27.27%	32.14%	27.78%	21.95%	50.00%	41.67%	30.77%	12.77%	-101.40%	-41.18%
Operating Cash Flow Growth	-43.58%	25.11%	10.55%	22.38%	57.40%	67.00%	59.09%	14.88%	4.39%	-57.66%
Free Cash Flow Firm Growth	-40.32%	15.49%	19.73%	49.13%	53.18%	43.94%	28.49%	-8.95%	-65.15%	25.95%
Invested Capital Growth	32.54%	12.43%	6.84%	-2.18%	8.49%	9.58%	8.69%	40.67%	32.38%	25.01%
Revenue Q/Q Growth	1.93%	9.37%	6.25%	0.62%	9.65%	-0.50%	14.08%	13.16%	14.63%	9.38%
EBITDA Q/Q Growth	8.14%	37.17%	19.75%	-62.59%	19.80%	26.13%	16.33%	5.55%	3.28%	7.36%
EBIT Q/Q Growth	7.08%	34.14%	18.47%	-56.58%	17.98%	24.53%	15.37%	8.69%	2.88%	6.85%
NOPAT Q/Q Growth	13.91%	31.89%	17.43%	-49.38%	15.11%	24.24%	5.59%	15.62%	3.33%	7.06%
Net Income Q/Q Growth	3.71%	27.44%	15.81%	-43.95%	14.57%	20.46%	12.06%	6.92%	5.42%	7.13%
EPS Q/Q Growth	15.79%	26.92%	18.75%	-45.45%	21.43%	22.22%	12.20%	6.82%	8.33%	7.69%
Operating Cash Flow Q/Q Growth	-178.25%	55.79%	48.19%	-125.32%	-45.13%	47.20%	55.04%	-23.65%	-12.44%	34.56%
Free Cash Flow Firm Q/Q Growth	-43.03%	17.08%	-4.69%	-13.02%	13.86%	21.23%	33.66%	-4.01%	-3.13%	-0.48%
Invested Capital Q/Q Growth	20.59%	-8.27%	-0.53%	20.45%	2.29%	-12.83%	-8.92%	33.59%	3.32%	-13.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.41%	73.22%	73.40%	73.62%	75.20%	74.47%	72.51%	71.67%	68.83%	71.39%
EBITDA Margin	-15.09%	-16.74%	-29.14%	-38.58%	-23.88%	-32.65%	-43.97%	-59.96%	-71.84%	-85.14%
Operating Margin	-17.02%	-20.15%	-32.35%	-41.63%	-28.04%	-36.22%	-47.57%	-57.48%	-77.09%	-91.41%
EBIT Margin	-17.42%	-19.11%	-31.73%	-41.35%	-26.57%	-35.52%	-46.83%	-63.13%	-78.23%	-92.34%
Profit (Net Income) Margin	-24.46%	-25.89%	-39.02%	-49.24%	-34.42%	-44.18%	-55.26%	-71.69%	-87.15%	-105.63%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	140.41%	135.49%	122.98%	119.10%	129.54%	124.37%	118.00%	113.56%	111.40%	114.40%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-73.40%	-93.10%	-125.73%	-148.17%	-119.82%	-146.37%	-152.31%	-166.52%	-272.22%	-312.45%
ROIC Less NNEP Spread (ROIC-NNEP)	123.88%	71.10%	-5.34%	-98.47%	-104.15%	-130.48%	-137.84%	-152.89%	-262.81%	-303.78%
Return on Net Nonoperating Assets (RNNOA)	-11.80%	-8.21%	0.90%	34.52%	63.87%	84.96%	93.18%	113.11%	219.01%	260.30%
Return on Equity (ROE)	-85.20%	-101.31%	-124.83%	-113.66%	-55.95%	-61.42%	-59.13%	-53.40%	-53.21%	-52.15%
Cash Return on Invested Capital (CROIC)	-144.96%	-151.13%	-140.67%	-133.84%	-185.63%	-223.84%	-219.52%	-268.26%	-344.33%	-334.50%
Operating Return on Assets (OROA)	-13.76%	-14.94%	-23.18%	-27.85%	-15.68%	-19.46%	-23.30%	-26.09%	-28.76%	-30.85%
Return on Assets (ROA)	-19.32%	-20.24%	-28.51%	-33.16%	-20.31%	-24.20%	-27.50%	-29.63%	-32.04%	-35.30%
Return on Common Equity (ROCE)	-85.20%	-101.31%	-124.83%	-113.66%	-55.95%	-61.42%	-59.13%	-53.40%	-53.21%	-52.15%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-285.97%	-302.44%	-219.69%	0.00%	-231.63%	-199.90%	-167.32%	0.00%	-107.42%
Net Operating Profit after Tax (NOPAT)	-2.56	-2.97	-4.36	-5.28	-3.54	-4.17	-5.50	-5.82	-6.90	-7.14
NOPAT Margin	-11.91%	-14.10%	-22.65%	-29.14%	-19.63%	-25.35%	-33.30%	-40.24%	-53.96%	-63.99%
Net Nonoperating Expense Percent (NNEP)	-197.28%	-164.20%	-120.39%	-49.70%	-15.67%	-15.89%	-14.47%	-13.62%	-9.41%	-8.67%
Return On Investment Capital (ROIC_SIMPLE)	-3.79%	-	-	-	-4.56%	-	-	-	-	-
Cost of Revenue to Revenue	24.59%	26.78%	26.60%	26.38%	24.80%	25.53%	27.49%	28.33%	31.17%	28.61%
SG&A Expenses to Revenue	64.25%	66.04%	74.26%	83.34%	73.39%	81.50%	87.72%	92.79%	106.13%	112.51%
R&D to Revenue	28.18%	27.32%	31.50%	31.91%	29.85%	29.19%	32.36%	36.37%	39.79%	50.29%
Operating Expenses to Revenue	92.43%	93.37%	105.75%	115.25%	103.24%	110.69%	120.08%	129.15%	145.92%	162.80%
Earnings before Interest and Taxes (EBIT)	-3.74	-4.02	-6.11	-7.49	-4.79	-5.84	-7.73	-9.14	-10	-10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.24	-3.53	-5.61	-6.99	-4.30	-5.36	-7.26	-8.68	-9.19	-9.50
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	41.68	20.72	22.00	26.09	13.12	15.38	5.37	4.24	1.07	2.15
Price to Tangible Book Value (P/TBV)	41.68	20.72	22.00	26.09	13.12	15.38	5.37	4.24	1.07	2.15
Price to Revenue (P/Rev)	4.18	2.66	3.03	5.42	4.14	4.18	2.08	2.40	0.82	2.13
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.05	16.80	16.53	27.78	23.44	22.57	8.42	7.48	1.23	6.00
Enterprise Value to Revenue (EV/Rev)	4.26	2.69	3.08	5.40	4.00	4.09	1.92	2.11	0.28	1.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	7.43	6.03	5.97	4.05	2.76	3.42	2.58	1.96	1.52	1.20
Long-Term Debt to Equity	7.43	6.03	5.97	4.05	2.76	3.42	2.58	1.96	1.52	1.20
Financial Leverage	-0.10	-0.12	-0.17	-0.35	-0.61	-0.65	-0.68	-0.74	-0.83	-0.86
Leverage Ratio	7.06	7.47	6.32	4.90	4.00	3.68	2.98	2.60	2.29	2.09
Compound Leverage Factor	9.91	10.12	7.77	5.84	5.18	4.57	3.51	2.96	2.55	2.39
Debt to Total Capital	88.14%	85.78%	85.65%	80.19%	73.39%	77.35%	72.10%	66.21%	60.34%	54.48%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	88.14%	85.78%	85.65%	80.19%	73.39%	77.35%	72.10%	66.21%	60.34%	54.48%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	11.86%	14.22%	14.35%	19.81%	26.61%	22.65%	27.90%	33.79%	39.66%	45.52%
Debt to EBITDA	-3.07	-2.90	-2.65	-2.43	-2.22	-1.83	-1.58	-1.43	-1.40	-1.38
Net Debt to EBITDA	-0.35	-0.12	-0.16	0.04	0.37	0.18	0.25	0.37	0.65	0.89
Long-Term Debt to EBITDA	-3.07	-2.90	-2.65	-2.43	-2.22	-1.83	-1.58	-1.43	-1.40	-1.38
Debt to NOPAT	-3.92	-3.67	-3.40	-3.14	-2.99	-2.50	-2.16	-1.96	-1.85	-1.86
Net Debt to NOPAT	-0.45	-0.15	-0.20	0.05	0.50	0.24	0.34	0.50	0.86	1.20
Long-Term Debt to NOPAT	-3.92	-3.67	-3.40	-3.14	-2.99	-2.50	-2.16	-1.96	-1.85	-1.86
Altman Z-Score	-3.99	-4.73	-4.77	-3.29	-3.37	-3.92	-4.70	-4.37	-4.47	-3.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.37	5.59	6.37	6.43	5.71	6.55	7.52	9.13	8.90	11.08
Quick Ratio	4.33	4.63	5.31	5.38	4.85	5.67	6.47	7.78	7.73	9.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.19	-4.33	-5.22	-4.98	-4.41	-5.12	-6.50	-9.79	-9.42	-9.13
Operating Cash Flow to CapEx	-12,300.00%	-1,724.00%	-6,190.48%	-7,238.46%	-10,440.63%	-25,577.78%	0.00%	-7,346.97%	-7,689.22%	-22,500.00%
Free Cash Flow to Firm to Interest Expense	-2.82	-1.98	-2.41	-2.21	-1.97	-2.34	-3.06	-4.98	-4.85	-4.79
Operating Cash Flow to Interest Expense	-2.19	-0.79	-1.80	-3.33	-1.49	-1.05	-2.05	-4.94	-4.04	-3.66
Operating Cash Flow Less CapEx to Interest Expense	-2.21	-0.84	-1.83	-3.38	-1.51	-1.05	-2.05	-5.00	-4.09	-3.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.79	0.78	0.73	0.67	0.59	0.55	0.50	0.41	0.37	0.33
Accounts Receivable Turnover	6.35	6.69	6.49	6.63	6.61	6.29	5.68	5.33	6.25	6.04
Inventory Turnover	1.69	1.83	1.74	1.62	1.65	1.83	1.72	1.49	1.49	1.52
Fixed Asset Turnover	77.77	76.84	72.76	66.67	63.30	65.33	57.01	51.61	54.61	57.61
Accounts Payable Turnover	7.88	11.89	9.06	7.06	7.72	14.12	9.56	6.91	7.39	9.85
Days Sales Outstanding (DSO)	57.48	54.52	56.20	55.02	55.22	58.07	64.29	68.52	58.43	60.46
Days Inventory Outstanding (DIO)	215.58	199.22	210.15	224.99	220.76	199.02	212.70	245.55	245.64	240.19
Days Payable Outstanding (DPO)	46.33	30.71	40.28	51.74	47.25	25.85	38.19	52.84	49.38	37.06
Cash Conversion Cycle (CCC)	226.72	223.03	226.08	228.28	228.74	231.24	238.79	261.24	254.68	263.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	15	12	13	13	11	11	13	14	10	9.95
Invested Capital Turnover	6.16	6.60	5.55	5.08	6.10	5.77	4.57	4.14	5.04	4.88
Increase / (Decrease) in Invested Capital	3.63	1.36	0.86	-0.30	0.87	0.95	1.00	3.97	2.52	1.99
Enterprise Value (EV)	341	206	221	373	261	246	105	103	13	60
Market Capitalization	334	204	217	374	271	252	114	116	37	93
Book Value per Share	$0.27	$0.34	$0.34	$0.51	$0.79	$0.63	$0.84	$1.10	$1.40	$1.75
Tangible Book Value per Share	$0.27	$0.34	$0.34	$0.51	$0.79	$0.63	$0.84	$1.10	$1.40	$1.75
Total Capital	68	69	69	72	78	72	76	81	88	95
Total Debt	60	59	59	58	57	56	55	54	53	52
Total Long-Term Debt	60	59	59	58	57	56	55	54	53	52
Net Debt	6.77	2.44	3.48	-0.91	-9.50	-5.46	-8.72	-14	-24	-33
Capital Expenditures (CapEx)	0.04	0.10	0.06	0.10	0.03	0.01	0.00	0.13	0.10	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	11	12	12	10	9.81	11	13	9.33	9.54
Debt-free Net Working Capital (DFNWC)	66	68	68	71	76	71	75	80	87	95
Net Working Capital (NWC)	66	68	68	71	76	71	75	80	87	95
Net Nonoperating Expense (NNE)	2.69	2.48	3.15	3.64	2.66	3.09	3.63	4.55	4.24	4.65
Net Nonoperating Obligations (NNO)	6.77	2.44	3.48	-0.91	-9.50	-5.46	-8.72	-14	-24	-33
Total Depreciation and Amortization (D&A)	0.50	0.50	0.50	0.50	0.49	0.47	0.47	0.46	0.82	0.80
Debt-free, Cash-free Net Working Capital to Revenue	16.80%	14.36%	16.85%	17.66%	15.34%	16.30%	20.81%	26.05%	20.49%	21.82%
Debt-free Net Working Capital to Revenue	82.83%	88.70%	94.18%	103.00%	116.92%	118.21%	136.55%	165.13%	190.55%	217.14%
Net Working Capital to Revenue	82.83%	88.70%	94.18%	103.00%	116.92%	118.21%	136.55%	165.13%	190.55%	217.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	($0.19)	($0.26)	($0.32)	($0.22)	($0.28)	($0.36)	($0.41)	($0.44)	($0.48)
Adjusted Weighted Average Basic Shares Outstanding	29.13M	29.44M	28.85M	28.29M	25.85M	26.02M	25.47M	25.10M	24.59M	24.73M
Adjusted Diluted Earnings per Share	($0.16)	($0.19)	($0.26)	($0.32)	($0.22)	($0.28)	($0.36)	($0.41)	($0.44)	($0.48)
Adjusted Weighted Average Diluted Shares Outstanding	29.13M	29.44M	28.85M	28.29M	25.85M	26.02M	25.47M	25.10M	24.59M	24.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.56M	29.85M	29.20M	28.77M	28.34M	26.28M	25.86M	25.41M	25.10M	24.90M
Normalized Net Operating Profit after Tax (NOPAT)	-2.56	-2.97	-4.36	-5.28	-3.54	-4.17	-5.50	-5.82	-6.90	-7.14
Normalized NOPAT Margin	-11.91%	-14.10%	-22.65%	-29.14%	-19.63%	-25.35%	-33.30%	-40.24%	-53.96%	-63.99%
Pre Tax Income Margin	-24.46%	-25.89%	-39.02%	-49.24%	-34.42%	-44.18%	-55.26%	-71.69%	-87.15%	-105.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.71	-1.84	-2.82	-3.32	-2.14	-2.66	-3.64	-4.65	-5.15	-5.41
NOPAT to Interest Expense	-1.17	-1.36	-2.01	-2.34	-1.58	-1.90	-2.59	-2.96	-3.56	-3.75
EBIT Less CapEx to Interest Expense	-1.72	-1.89	-2.85	-3.36	-2.15	-2.67	-3.64	-4.72	-5.21	-5.42
NOPAT Less CapEx to Interest Expense	-1.18	-1.41	-2.04	-2.39	-1.60	-1.91	-2.59	-3.03	-3.61	-3.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.66%	-0.62%	-0.62%	-0.93%	-1.23%	-1.10%	-0.99%	-0.74%	0.00%

Frequently Asked Questions About NeuroPace's Financials

When does NeuroPace's financial year end?

According to the most recent income statement we have on file, NeuroPace's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NeuroPace's net income changed over the last 2 years?

NeuroPace's net income appears to be on a downward trend, with a most recent value of -$27.14 million in 2024, falling from -$47.08 million in 2022. The previous period was -$32.96 million in 2023. Find out what analysts predict for NeuroPace in the coming months.

What is NeuroPace's operating income?

NeuroPace's total operating income in 2024 was -$21.67 million, based on the following breakdown:

Total Gross Profit: $59.09 million
Total Operating Expenses: $80.76 million

How has NeuroPace revenue changed over the last 2 years?

Over the last 2 years, NeuroPace's total revenue changed from $45.52 million in 2022 to $79.91 million in 2024, a change of 75.5%.

How much debt does NeuroPace have?

NeuroPace's total liabilities were at $86.63 million at the end of 2024, a 0.4% decrease from 2023, and a 9.2% increase since 2022.

How much cash does NeuroPace have?

In the past 2 years, NeuroPace's cash and equivalents has ranged from $6.61 million in 2022 to $18.06 million in 2023, and is currently $13.43 million as of their latest financial filing in 2024.

How has NeuroPace's book value per share changed over the last 2 years?

Over the last 2 years, NeuroPace's book value per share changed from 1.40 in 2022 to 0.27 in 2024, a change of -80.8%.

Related Companies

This page (NASDAQ:NPCE) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Financials

Frequently Asked Questions About NeuroPace's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Financials

Annual Income Statements for NeuroPace

Quarterly Income Statements for NeuroPace

Annual Cash Flow Statements for NeuroPace

Quarterly Cash Flow Statements for NeuroPace

Annual Balance Sheets for NeuroPace

Quarterly Balance Sheets for NeuroPace

Annual Metrics And Ratios for NeuroPace

Quarterly Metrics And Ratios for NeuroPace

Frequently Asked Questions About NeuroPace's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools